Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy

被引:0
作者
Martina A. Broglie
Alex Soltermann
Sarah R. Haile
Gerhard F. Huber
Sandro J. Stoeckli
机构
[1] Kantonsspital St. Gallen,Department of Otorhinolaryngology, Head and Neck Surgery
[2] University Hospital of Zurich,Institute of Surgical Pathology
[3] Kantonsspital St. Gallen,Clinical Trials Unit
[4] University Hospital of Zurich,Department of Otorhinolaryngology, Head and Neck Surgery
来源
European Archives of Oto-Rhino-Laryngology | 2015年 / 272卷
关键词
Oropharyngeal cancer; Surgery; Survival; Human papillomavirus; p16; p53;
D O I
暂无
中图分类号
学科分类号
摘要
Impact of p16 protein, a surrogate marker for human papilloma virus induced cancer, p53 and EGFR as well as clinical factors on survival in a patient cohort with oropharyngeal squamous cell carcinoma (OPSCC) treated by surgical resection and adjuvant radiotherapy (RT) ± concomitant chemotherapy (CT). This is a retrospective analysis of patient’s charts and tumor tissue. 57 patients were consecutively included and their tumor tissue assembled on a tissue microarray following immunohistochemical analysis. Survival times were estimated by means of Kaplan–Meier analysis. The importance of clinical and immunohistochemical factors for outcome was estimated by cox proportional hazard models. With 88 % 5-year overall survival, 91 % 5-year disease-specific survival and 91 % 5-year disease-free survival, respectively, we found excellent survival rates in this surgically treated patient cohort of mainly advanced OPSCC (93 % AJCC stage III or IV). The only factors positively influencing survival were p16 overexpression as well as p53 negativity and even more pronounced the combination of those biomarkers. Survival analysis of patients classified into three risk categories according to an algorithm based on p16, smoking, T- and N-category revealed a low, intermediate and high-risk group with significant survival differences between the low and the high-risk group. Patients with OPSCC can be successfully treated by surgery and adjuvant RT ± CT with a clear survival benefit of p16 positive, p53 negative patients. We recommend considering a combination of immunohistochemical (p16, p53) and clinical factors (smoking, T- and N-category) for risk stratification.
引用
收藏
页码:1755 / 1762
页数:7
相关论文
共 228 条
  • [1] Tschudi D(2003)Quality of life after different treatment modalities for carcinoma of the oropharynx Laryngoscopes 113 1949-1954
  • [2] Stoeckli S(2006)Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers J Clin Oncol 24 5623-5625
  • [3] Schmid S(2001)Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck N Engl J Med 344 1125-1131
  • [4] Gillison ML(2012)Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev Med Virol 22 88-105
  • [5] Mork J(2008)Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial J Natl Cancer Inst 100 261-269
  • [6] Lie AK(2010)Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 24-35
  • [7] Glattre E(2001)Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma Cancer 92 805-813
  • [8] Hallmans G(2007)Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7 Mol Oncol 1 350-355
  • [9] Jellum E(1996)Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis Int J Cancer 68 506-513
  • [10] Koskela P(1996)The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy Radiother Oncol 40 197-223